TrianglePUBLICATIONS · 34618601
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2021 Dec 1
- First author
- Wierda WG
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Wierda WG
- type
- Author
- name
- Allan JN
- type
- Author
- name
- Siddiqi T
- type
- Author
- name
- Kipps TJ
- type
- Author
- name
- Opat S
- type
- Author
- name
- Tedeschi A
- type
- Author
- name
- Badoux XC
- type
- Author
- name
- Kuss BJ
- type
- Author
- name
- Jackson S
- type
- Author
- name
- Moreno C
- type
- Author
- name
- Jacobs R
- type
- Author
- name
- Pagel JM
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Wierda WG
- type
- Author
- name
- Allan JN
- type
- Author
- name
- Siddiqi T
- type
- Author
- name
- Kipps TJ
- type
- Author
- name
- Opat S
- type
- Author
- name
- Tedeschi A
- type
- Author
- name
- Badoux XC
- type
- Author
- name
- Kuss BJ
- type
- Author
- name
- Jackson S
- type
- Author
- name
- Moreno C
- type
- Author
- name
- Jacobs R
- type
- Author
- name
- Pagel JM
- type
- Author
- bibliography ids
- nci-bib-117ece82ba8dea585aa669d3
- book metadata
- content sha256
- 8dec72c8ad3a2ec9d137e825191372c5d464223d67ba87bbadd89d2fb20a42e7
- document type
- citation
- dois
- 10.1200/JCO.21.00807
- electronic publication date
- display
- 2021 Oct 7
- precision
- day
- year
- 2021
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:34618601
- immutable id
- pubmed:34618601@8dec72c8ad3a2ec9d137e825191372c5d464223d67ba87bbadd89d2fb20a42e7
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 34
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 3853-3865
- volume
- 39
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 34618601
- provenance
- batch id
- 192b6392c165c6b06274
- provider
- NCBI PubMed ESummary
- record sha256
- 6aad24acaf72b7af943cd4c6b0cd9740ddec127a515fde6780fd498bc8957b46
- response sha256
- 7d81e9fb11ee99e6ad4116aecd61ba71cd6bf76f2a8f8f6d15c5c85e9c6c56b4
- retrieved at
- 2026-09-09T23:48:02.713075+00:00
- publication date
- display
- 2021 Dec 1
- precision
- day
- year
- 2021
- publication types
- Clinical Trial, Phase II
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
Preserved source evidence · Not medical advice